Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Details
Serval ID
serval:BIB_741CF7FE0871
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Journal
Antimicrobial agents and chemotherapy
ISSN
1098-6596 (Electronic)
ISSN-L
0066-4804
Publication state
Published
Issued date
19/04/2022
Peer-reviewed
Oui
Volume
66
Number
4
Pages
e0003922
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.
Keywords
Anti-Bacterial Agents/pharmacology, Anti-Bacterial Agents/therapeutic use, Azabicyclo Compounds/pharmacology, Aztreonam/pharmacology, Ceftazidime/pharmacology, Cephalosporins, Drug Combinations, Escherichia coli, Escherichia coli Infections/drug therapy, Humans, Lactams, Microbial Sensitivity Tests, Pseudomonas aeruginosa, beta-Lactamase Inhibitors/pharmacology, beta-Lactamases/genetics, cefiderocol, susceptibility testing, β-lactamase
Pubmed
Web of science
Create date
06/04/2022 20:08
Last modification date
07/11/2023 7:09
Usage data
